Short Interest Summary: Celldex Therapeutics Incorporated (NASDAQ:CLDX) Has Increase in Shorts

November 29, 2016 - By Marie Mckinney   ·   0 Comments

Short Interest Summary: Celldex Therapeutics Incorporated (NASDAQ:CLDX) Has Increase in Shorts

The stock of Celldex Therapeutics Incorporated (NASDAQ:CLDX) registered an increase of 5.67% in short interest. CLDX’s total short interest was 20.47M shares in November as published by FINRA. Its up 5.67% from 19.37 million shares, reported previously. With 1.54M shares average volume, it will take short sellers 13 days to cover their CLDX’s short positions. The short interest to Celldex Therapeutics Incorporated’s float is 20.48%. About 1.46 million shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 1.26% since April 26, 2016 and is downtrending. It has underperformed by 6.52% the S&P500.

Celldex Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $358.35 million. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. It currently has negative earnings. The Company’s lead drug Rintega is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Out of 12 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Celldex Therapeutics has been the topic of 16 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Neutral” rating by Guggenheim on Monday, March 7. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, February 26 report. On Monday, March 7 the stock rating was downgraded by Oppenheimer to “Perform”. The rating was maintained by Oppenheimer on Tuesday, August 11 with “Outperform”. Leerink Swann downgraded the shares of CLDX in a report on Monday, March 7 to “Market Perform” rating. As per Monday, March 7, the company rating was downgraded by Wedbush. The company was downgraded on Tuesday, March 8 by Jefferies. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Hold” rating given on Tuesday, August 9 by Jefferies. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Outperform” rating given on Tuesday, March 8 by Cowen & Co. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Buy” rating by Brean Capital on Tuesday, August 11.

CLDX Company Profile

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.

Another recent and important Celldex Therapeutics, Inc. (NASDAQ:CLDX) news was published by Fool.com which published an article titled: “Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today” on November 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>